Efficacy of levomilnacipran in improving symptoms and functional impairment associated with major depressive disorder

被引：1
|
作者：
Lecrubier, Y. [1 ]
Mansuy, L. [2 ]
Bose, A. [3 ]
Li, J.
Werner, P. [3 ]
机构：
[1] Hop La Pitie Salpetriere, Natl Inst Hlth & Med Res, INSERM, Paris, France
[2] Pierre Fabre Med, Toulouse, France
[3] Forest Res Inst, CNS Med Affairs, Jersey City, NJ USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2010年 / 20卷
关键词：
D O I：
10.1016/S0924-977X(10)70553-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S390 / S390
页数：1
相关论文
共 50 条
  • [1] Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
    Freeman, Marlene P.
    Fava, Maurizio
    Gommoll, Carl
    Chen, Changzheng
    Greenberg, William M.
    Ruth, Adam
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2016, 31 (02) : 100 - 109
  • [2] Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
    Sambunaris, Angelo
    Gommoll, Carl
    Chen, Changzheng
    Greenberg, William M.
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (04) : 197 - 205
  • [3] Clinical relevance of levomilnacipran ER treatment in major depressive disorder: improvements in functional impairment categories
    Cutler, A.
    Gommoll, C.
    Chen, C.
    Greenberg, W. M.
    Ruth, A.
    D'Souza, I.
    Terner-Rosenthal, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S461 - S461
  • [4] Efficacy of levomilnacipran extended release in treating major depressive disorder
    Ragguett, Renee-Marie
    Yim, Samantha J.
    Ho, Peter T.
    McIntyre, Roger S.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (18) : 2017 - 2024
  • [5] LEVOMILNACIPRAN: A REVIEW OF ITS BIODISPOSITION AND EFFICACY IN MAJOR DEPRESSIVE DISORDER
    Findling, Robert
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S344 - S345
  • [6] EFFICACY OF DULOXETINE ON FUNCTIONAL IMPAIRMENT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Sheehan, David V.
    Meyers, Adam L.
    Ahl, Jonna
    Prakash, Apurva
    Oakes, Tina Marie Myers
    Kelin, Katarina
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2011, 45 : A63 - A63
  • [7] Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials
    Blier, Pierre
    Gommoll, Carl
    Chen, Changzheng
    Kramer, Kenneth
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2017, 210 : 273 - 279
  • [8] Levomilnacipran (Fetzima) for Major Depressive Disorder
    Zaman, Samira
    Mclaughlin, Maura R.
    [J]. AMERICAN FAMILY PHYSICIAN, 2015, 92 (08) : 727 - 731
  • [9] Clinical relevance of levomilnacipran er treatment in patients with major depressive disorder: Improvements in functional impairment categories
    Cutler, A.
    Gommoll, C.
    Chen, C.
    Greenberg, W. M.
    Ruth, A.
    Reese, A. Ho
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 60 - 60
  • [10] Levomilnacipran for the treatment of major depressive disorder: a review
    Asnis, Gregory M.
    Henderson, Margaret A.
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 125 - 135
12345